Show simple item record

dc.contributor.supervisorQing, Gefei (Pathology)en_US
dc.contributor.authorXu, Minqi
dc.date.accessioned2017-08-29T19:41:51Z
dc.date.available2017-08-29T19:41:51Z
dc.date.issued2017
dc.identifier.urihttp://hdl.handle.net/1993/32390
dc.description.abstractIntroduction: Modern care of patients with lung cancer requires rapid and accurate diagnosis leading to personalized therapies for individual patients based on molecular characteristics of their tumour. Detecting mutations that predict response to drug quickly and accurately is an essential part of this process. Next generation sequencing (NGS) technologies provide an alternative approach for detecting mutated oncogenes in cancer. We hypothesize that NGS is equal if not superior to standard methods for identifying targetable mutations in the EGFR and ALK genes in lung cancer. Methods: DNA and RNA from 38 formalin fixed paraffin embedded lung cancer samples (37 non-small cell lung cancer (NSCLC) and one small cell lung cancer (SCLC)) archived in Diagnostic Services Manitoba were collected and analyzed using gene enrichment methods from Archer Diagnostics followed by sequencing on the Illumina MiSeq NGS machine. Targeted DNA sequencing to detect the EGFR mutation was performed on 19 samples while targeted RNA sequencing was applied to 20 samples to identify the ALK gene rearrangement. The NGS results were compared with and confirmed by current clinical standard molecular tests for EGFR (real-time PCR) and ALK (immunohistochemistry and FISH). Results: Three cases were positive for the EGFR mutation and two other samples harbored the EML4-ALK fusion genes as determined by NGS. The concordance between NGS and real-time PCR for EGFR mutation detection was 88.9%. Additionally, the NGS methodology also provided profiles of other genes commonly mutated in NSCLC including KRAS and TP53. The consistency for ALK fusion testing was 100% between NGS and FISH. Conclusion: This study provides support that NGS is a promising diagnostic tool for mutation detection in NSCLC and holds strong potential for an alternative approach to identifying clinically relevant targets such as EGFR and ALK. Furthermore, NGS provides more information on cancer driven gene mutations than other traditional methods.en_US
dc.language.isoengen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectnext generation sequencingen_US
dc.subjectlung canceren_US
dc.subjectALKen_US
dc.subjectEGFRen_US
dc.titleUsing next generation sequencing to detect clinically relevant oncogene mutations in lung canceren_US
dc.typeinfo:eu-repo/semantics/masterThesis
dc.typemaster thesisen_US
dc.degree.disciplinePathologyen_US
dc.contributor.examiningcommitteeMyal, Yvonne (Pathology) Banerji, Shantanu (Internal Medicine)en_US
dc.degree.levelMaster of Science (M.Sc.)en_US
dc.description.noteOctober 2017en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record